Prudential Financial
SPRO icon

Prudential Financial’s Spero Therapeutics SPRO Stock Holding History

Prudential Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23K Buy
+10,400
New +$27.2K ﹤0.01% 2470
2025
Q2 		– Sell
-56,000
Closed -$40.3K – 2506
2025
Q1 		$40.3K Buy
56,000
+6,800
+14% +$5.74K ﹤0.01% 2215
2024
Q4 		$50.7K Buy
+49,200
New +$58.5K ﹤0.01% 2208
2024
Q2 		– Sell
-25,400
Closed -$43.7K – 2782
2024
Q1 		$43.7K Sell
25,400
-2,800
-10% -$4.39K ﹤0.01% 2604
2023
Q4 		$41.5K Hold
28,200
– – ﹤0.01% 2570
2023
Q3 		$34.1K Buy
28,200
+3,800
+16% +$5.26K ﹤0.01% 2536
2023
Q2 		$35.4K Buy
+24,400
New +$41.8K ﹤0.01% 2566
2023
Q1 		– Sell
-14,600
Closed -$25.3K – 2665
2022
Q4 		$25.3K Buy
+14,600
New +$27.3K ﹤0.01% 2555

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prudential Financial's SPRO Position: Q2 2026 in Review

Prudential Financial opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 10,400 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #2470 among its holdings. This is a return to the name: Prudential Financial previously reported a position in SPRO as recently as Q1 2025.

Prudential Financial first reported a position in SPRO in Q4 2022 and has held it in 8 quarters since. The position peaked at $50.7K in Q4 2024. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Prudential Financial held 10,400 shares of Spero Therapeutics worth $23K as of Q2 2026.
  • Spero Therapeutics was a new Prudential Financial position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2470 holding.
  • Prudential Financial first reported a position in Spero Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • Prudential Financial's Spero Therapeutics position peaked at $50.7K in Q4 2024.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.